Skip to main content
. Author manuscript; available in PMC: 2017 Sep 20.
Published in final edited form as: Nat Genet. 2017 Mar 20;49(5):730–741. doi: 10.1038/ng.3817

Figure 5. Clinical significance of validated genes in human prostate cancer.

Figure 5

(a) ZBTB20, CELF2, PARD3, AKAP13 and WAC mRNAs are significantly downregulated in primary prostate cancers (n=336) compared to normal tissue samples (n=65) available from TCGA. (b) mRNA levels of these genes were further reduced in metastatic samples (n=29) compared to primary tumors (n=131) available from the Taylor dataset. (a,b) Boxplots display the 25th to 75th percentiles (boxes), medians (lines), and 1.5 times the interquartile range (whiskers). *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student’s t test. (c,d) Scattered plots show positive correlations between PTEN and ZBTB20, CELF2, PARD3 and WAC gene expression in primary prostate tumors from the TCGA dataset (c) and in primary and metastatic tumors from the Taylor (d) dataset (in d, correlation is also detected for AKAP13). R, Pearson correlation coefficient. P-values were calculated by Pearson’s correlation test. Normalized RSEM and log2 mRNA expression values are shown respectively for the TCGA (a,c) and Taylor (b,d) datasets. (e) Recurrence-free survival Kaplan-Meier analysis of 25% of patients with lowest mRNA expression levels of each of the five genes above versus the remaining 75%. Analyses were performed using the Taylor dataset and the open web interface ‘Project Betastasis’ (see URLs section). P-values were obtained by log-rank test.